|
|
 Previous Article | Table of Contents | Next Article 
Marrow Transplants From Unrelated Donors for Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Jorge Sierra,
Jerry Radich,
John A. Hansen,
Paul J. Martin,
Effie W. Petersdorf,
Jeanie Bjerke,
Eileen Bryant,
Richard A. Nash,
Jean E. Sanders,
Rainer Storb,
Keith M. Sullivan,
Frederick R. Appelbaum, and
Claudio Anasetti
From the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA.
Transplantation of marrow from unrelated donors was investigated in patients with Philadelphia chromosome-positive (Ph1+) acute lymphoblastic leukemia (ALL) who lacked a suitable family donor. Eighteen patients underwent transplantation at our center between 1988 and 1995. The median patient age was 25 years (range, 1.7 to 51 years). Seven patients were in first complete remission, 1 in second remission, 3 in first relapse, and the remaining 7 had more advanced or chemotherapy refractory leukemia at transplant. All patients were conditioned with cyclophosphamide and total body irradiation followed by marrow transplants from closely HLA-matched, unrelated volunteers. Posttransplant graft-versus-host disease (GVHD) prophylaxis included methotrexate with either cyclosporine or FK506. Graft failure was not observed. Severe (grades III-IV) GVHD appeared in 6 of 17 evaluable patients and chronic extensive GVHD in 7 of 13 patients at risk. Five patients had recurrent ALL after transplantation and another 4 died from causes other than leukemia. Six patients transplanted in first remission, 2 in first relapse, and 1 in second remission remain alive and leukemia-free at a median follow-up of 17 months (range, 9 to 73 months). The probability of leukemia-free survival at 2 years is 49% ± 12%. These data indicate that unrelated donor marrow transplantation is an effective treatment option for patients with early stage Ph1+ ALL without a family match and suggest that in such patients an unrelated donor search should be initiated as soon as possible after diagnosis.
Blood, Vol. 90 No. 4 (August 15), 1997:
pp. 1410-1414
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. K. Fielding, J. M. Rowe, S. M. Richards, G. Buck, A. V. Moorman, I. J. Durrant, D. I. Marks, A. K. McMillan, M. R. Litzow, H. M. Lazarus, et al.
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993
Blood,
May 7, 2009;
113(19):
4489 - 4496.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Laport, J. C. Alvarnas, J. M. Palmer, D. S. Snyder, M. L. Slovak, A. M. Cherry, R. M. Wong, R. S. Negrin, K. G. Blume, and S. J. Forman
Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen
Blood,
August 1, 2008;
112(3):
903 - 909.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Carpenter, D. S. Snyder, M. E. D. Flowers, J. E. Sanders, T. A. Gooley, P. J. Martin, F. R. Appelbaum, and J. P. Radich
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia
Blood,
April 1, 2007;
109(7):
2791 - 2793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Yakoub-Agha, F. Mesnil, M. Kuentz, J. M. Boiron, N. Ifrah, N. Milpied, S. Chehata, H. Esperou, J.-P. Vernant, M. Michallet, et al.
Allogeneic Marrow Stem-Cell Transplantation From Human Leukocyte Antigen-Identical Siblings Versus Human Leukocyte Antigen-Allelic-Matched Unrelated Donors (10/10) in Patients With Standard-Risk Hematologic Malignancy: A Prospective Study From the French Society of Bone Marrow Transplantation and Cell Therapy
J. Clin. Oncol.,
December 20, 2006;
24(36):
5695 - 5702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Wassmann, H. Pfeifer, N. Goekbuget, D. W. Beelen, J. Beck, M. Stelljes, M. Bornhauser, A. Reichle, J. Perz, R. Haas, et al.
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)
Blood,
September 1, 2006;
108(5):
1469 - 1477.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yanada, J. Takeuchi, I. Sugiura, H. Akiyama, N. Usui, F. Yagasaki, T. Kobayashi, Y. Ueda, M. Takeuchi, S. Miyawaki, et al.
High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group
J. Clin. Oncol.,
January 20, 2006;
24(3):
460 - 466.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Sanders, K. A. Guthrie, P. A. Hoffmeister, A. E. Woolfrey, P. A. Carpenter, and F. R. Appelbaum
Final adult height of patients who received hematopoietic cell transplantation in childhood
Blood,
February 1, 2005;
105(3):
1348 - 1354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Towatari, M. Yanada, N. Usui, J. Takeuchi, I. Sugiura, M. Takeuchi, F. Yagasaki, Y. Kawai, S. Miyawaki, S. Ohtake, et al.
Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia
Blood,
December 1, 2004;
104(12):
3507 - 3512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. W. Petersdorf, C. Anasetti, P. J. Martin, T. Gooley, J. Radich, M. Malkki, A. Woolfrey, A. Smith, E. Mickelson, and J. A. Hansen
Limits of HLA mismatching in unrelated hematopoietic cell transplantation
Blood,
November 1, 2004;
104(9):
2976 - 2980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Harata, Y. Soda, K. Tani, J. Ooi, T. Takizawa, M. Chen, Y. Bai, K. Izawa, S. Kobayashi, A. Tomonari, et al.
CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells
Blood,
September 1, 2004;
104(5):
1442 - 1449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Thomas, S. Faderl, J. Cortes, S. O'Brien, F. J. Giles, S. M. Kornblau, G. Garcia-Manero, M. J. Keating, M. Andreeff, S. Jeha, et al.
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
Blood,
June 15, 2004;
103(12):
4396 - 4407.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Stone
The Difficult Problem of Acute Myeloid Leukemia in the Older Adult
CA Cancer J Clin,
November 1, 2002;
52(6):
363 - 371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. G. Ottmann, B. J. Druker, C. L. Sawyers, J. M. Goldman, J. Reiffers, R. T. Silver, S. Tura, T. Fischer, M. W. Deininger, C. A. Schiffer, et al.
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
Blood,
August 28, 2002;
100(6):
1965 - 1971.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Woolfrey, C. Anasetti, B. Storer, K. Doney, L. A. Milner, E. L. Sievers, P. Carpenter, P. Martin, E. Petersdorf, F. R. Appelbaum, et al.
Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children
Blood,
March 15, 2002;
99(6):
2002 - 2008.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hoelzer, N. Gokbuget, O. Ottmann, C.-H. Pui, M. V. Relling, F. R. Appelbaum, J. J.M. van Dongen, and T. Szczepanski
Acute Lymphoblastic Leukemia
Hematology,
January 1, 2002;
2002(1):
162 - 192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Cornelissen, M. Carston, C. Kollman, R. King, A. W. Dekker, B. Lowenberg, and C. Anasetti
Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome
Blood,
March 15, 2001;
97(6):
1572 - 1577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Soiffer, E. Weller, E. P. Alyea, P. Mauch, I. L. Webb, D. C. Fisher, A. S. Freedman, R. L. Schlossman, J. Gribben, S. Lee, et al.
CD6+ Donor Marrow T-Cell Depletion as the Sole Form of Graft-Versus-Host Disease Prophylaxis in Patients Undergoing Allogeneic Bone Marrow Transplant From Unrelated Donors
J. Clin. Oncol.,
February 15, 2001;
19(4):
1152 - 1159.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Wheeler, S. M. Richards, C. C. Bailey, B. Gibson, I. M. Hann, F. G. H. Hill, and J. M. Chessells
Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: results from Medical Research Council UKALL X and XI
Blood,
October 1, 2000;
96(7):
2412 - 2418.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Nash, J. H. Antin, C. Karanes, J. W. Fay, B. R. Avalos, A. M. Yeager, D. Przepiorka, S. Davies, F. B. Petersen, P. Bartels, et al.
Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
Blood,
September 15, 2000;
96(6):
2062 - 2068.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Green, E. Clarke, L. Hunt, A. Canterbury, A. Lankester, G. Hale, H. Waldmann, S. Goodman, J. M. Cornish, D. I. Marks, et al.
Children With Acute Lymphoblastic Leukemia Who Receive T-Cell-Depleted HLA Mismatched Marrow Allografts From Unrelated Donors Have an Increased Incidence of Primary Graft Failure but a Similar Overall Transplant Outcome
Blood,
October 1, 1999;
94(7):
2236 - 2246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schrappe, M. Arico, J. Harbott, A. Biondi, M. Zimmermann, V. Conter, A. Reiter, M. G. Valsecchi, H. Gadner, G. Basso, et al.
Philadelphia Chromosome-Positive (Ph+) Childhood Acute Lymphoblastic Leukemia: Good Initial Steroid Response Allows Early Prediction of a Favorable Treatment Outcome
Blood,
October 15, 1998;
92(8):
2730 - 2741.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui and W. E. Evans
Acute Lymphoblastic Leukemia
N. Engl. J. Med.,
August 27, 1998;
339(9):
605 - 615.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Rubnitz and C.-H. Pui
Childhood Acute Lymphoblastic Leukemia
Oncologist,
December 1, 1997;
2(6):
374 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
